New diabetes clinical trial: Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
Published on: October 16, 2024 at 11:00PM
Conditions: Relapsed Refractory Multiple Myeloma (RRMM)
Interventions: Drug: Elranatamab; Drug: Mezigdomide; Drug: Dexamethasone
Sponsors: YOUNGIL KOH
Not yet recruiting
https://ift.tt/3AtgSUj
Conditions: Relapsed Refractory Multiple Myeloma (RRMM)
Interventions: Drug: Elranatamab; Drug: Mezigdomide; Drug: Dexamethasone
Sponsors: YOUNGIL KOH
Not yet recruiting
https://ift.tt/3AtgSUj
Comments
Post a Comment